When Medical Journals Are Big Pharma Infomercials

<a href="http://www.flickr.com/photos/charlie_brown_in/4813687658/">Pranjal Mahna</a>/Flickr

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


The days when Big Pharma showered doctors with branded coffee mugs, pens, notepads, and other freebies ended in 2008, when many pharmaceutical companies voluntarily agreed to stop doling out drug tchotchkes in an attempt to curry favor. Now, the multi-billion dollar pharmaceutical industry’s influence is more subtle.

A new article in the American Scholar notes that Big Pharma is quietly manipulating the contents of trusted medical journals. As the former editor of the British Medical Journal, Richard Smith, told writer Harriet Washington, “All journals are bought—or at least cleverly used—by the pharmaceutical industry.”

Below, a look at the American Scholar‘s findings:

First, it starts with heavy advertising—revenue that many medical journals need to stay in print. Then, drug makers leverage the financial power from their ad dollars to pressure journals into excluding drug research trials that show negative or ineffective results. It doesn’t end there, though. According to the American Scholar, many drug-reviewing experts published in medical journals are paid by drug makers. Reviewer’s bias, anyone?

Doctors rely on medical journals for the newest pharmaceutical research findings and unbiased scientific insight into their field. “When you are published in a medical journal, especially one of the top ones, this gives the article a certain imprimatur that makes people less critical,” says bioethicist Joel Lexchin. The American Scholar article notes that when these journals’ objectivity is compromised, doctors may believe that “medications in trials are more effective than they are.” Click here to read the American Scholar piece.

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We've never been very good at being conservative.

And usually, that serves us well in doing the ambitious, hard-hitting journalism that you turn to Mother Jones for. But it also means we can't afford to come up short when it comes to scratching together the funds it takes to keep our team firing on all cylinders, and the truth is, we finished our budgeting cycle on June 30 about $100,000 short of our online goal.

This is no time to come up short. It's time to fight like hell, as our namesake would tell us to do, for a democracy where minority rule cannot impose an extreme agenda, where facts matter, and where accountability has a chance at the polls and in the press. If you value our reporting and you can right now, please help us dig out of the $100,000 hole we're starting our new budgeting cycle in with an always-needed and always-appreciated donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate